放射性标记PSMA配体PET对新诊断前列腺癌患者肿瘤分期的诊断准确性:与组织病理学比较的系统评价与Meta分析
该系统评价与Meta分析纳入23篇文献共969例患者,评估放射性标记PSMA配体PET/CT与PET/MRI对新诊断前列腺癌肿瘤分期的诊断准确性,以组织病理学为参考标准。结果显示PSMA PET/MRI检测前列腺内肿瘤的准确性为97%(95%CI:94-100%),PSMA PET/CT为86%(95%CI:76-96%);检测精囊腺受累分别为90%(95%CI:82-99%)和87%(95%CI:80-93%);检测前列腺外侵犯分别为77%(95%CI:69-85%)和73%(95%CI:64-82%)。作者结论认为PSMA PET/MRI在诊断准确性上超过目前推荐的多参数MRI(mpMRI),而PSMA PET/CT与mpMRI相当。
要点
- PSMA PET/MRI检测前列腺内肿瘤的准确性为97%(95%CI:94-100%),PSMA PET/CT为86%(95%CI:76-96%)。
- 检测精囊腺受累:PSMA PET/MRI为90%(95%CI:82-99%),PSMA PET/CT为87%(95%CI:80-93%)。
- 检测前列腺外侵犯:PSMA PET/MRI为77%(95%CI:69-85%),PSMA PET/CT为73%(95%CI:64-82%)。
核心结论
- 作者认为PSMA PET/MRI在诊断准确性上超过目前推荐的多参数MRI(mpMRI),而PSMA PET/CT检测前列腺内肿瘤和T分期的诊断准确性与mpMRI相当。
- 分析发现小样本效应和潜在发表偏倚可能影响本研究的总体结论。
研究设计与样本
- 系统评价与Meta分析,系统检索PubMed、Embase、Web of Science和Cochrane Library数据库。
- 纳入23篇科学论文共969例患者,以组织病理学为参考标准,按患者水平采用随机效应Sidik-Jonkman模型估计诊断准确性及95%CI。
- 由两名独立评价者按预定纳入标准评估研究、提取数据并评价证据质量,分歧由第三名评价者解决。
- 采用Egger检验和漏斗图图形检查评估发表偏倚可能性和小样本效应影响。
主要发现
- PSMA PET/CT和PSMA PET/MRI检测前列腺内肿瘤(原发肿瘤)的诊断准确性分别为86%(95%CI:76-96%)和97%(95%CI:94-100%),不考虑PSMA配体类型。
- 检测前列腺外侵犯(EPE)的诊断准确性:PSMA PET/CT为73%(95%CI:64-82%),PSMA PET/MRI为77%(95%CI:69-85%)。
- 检测精囊腺受累(SVI)的诊断准确性:PSMA PET/CT为87%(95%CI:80-93),PSMA PET/MRI为90%(95%CI:82-99%)。
关键数值与推荐
- PSMA PET/CT检测前列腺内肿瘤准确性86%(95%CI:76-96%),PSMA PET/MRI为97%(95%CI:94-100%)。
- PSMA PET/CT检测前列腺外侵犯准确性73%(95%CI:64-82%),PSMA PET/MRI为77%(95%CI:69-85%)。
- PSMA PET/CT检测精囊腺受累准确性87%(95%CI:80-93),PSMA PET/MRI为90%(95%CI:82-99%)。
临床怎么用
- 作者认为PSMA PET/MRI在诊断准确性上超过目前推荐的多参数MRI(mpMRI)。
- 作者认为PSMA PET/CT检测前列腺内肿瘤和T分期的诊断准确性与mpMRI相当。
局限性
- 分析发现小样本效应(small-study effects)。
- 分析发现潜在发表偏倚,可能影响本研究的总体结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The current clinical recommendations posit the deployment of specific approved radiolabeled prostate-specific membrane antigen-ligand positron emission tomography (PSMA PET) for detecting metastatic prostate cancer during primary staging. Nevertheless, the precise efficacy of such ligands in localizing intraprostatic tumours (index tumour) and T-staging is not well established. Consequently, the objective of this inquiry is to ascertain the diagnostic accuracy of PSMA-PET in the tumour staging of newly diagnosed prostate cancer by means of a meta-analysis that integrates studies utilizing histological confirmation as the reference standard. METHODS: In this study, we conducted a systematic literature search of the PubMed, Embase, Web of Science, and Cochrane Library databases using a predefined collection of search terms. These terms included 'PSMA PET', 'primary staging', and 'prostate cancer'. Subsequently, two independent reviewers evaluated all the studies based on predetermined inclusion criteria, extracted pertinent data, and assessed the quality of evidence. Any disparities were resolved by a third reviewer. A random effects Sidik-Jonkman model was applied to conduct a meta-analysis and estimate the diagnostic accuracy on a per-patient basis, along with 95% confidence intervals. Moreover, an appraisal regarding the likelihood of publication bias and the impact of small-study effects was performed utilizing both Egger's test and a graphical examination of the funnel plot. RESULTS: The present analysis comprised a total of twenty-three scientific papers encompassing 969 patients and involved their analysis by both qualitative and quantitative approaches. The results of this study demonstrated that the estimated diagnostic accuracy of PSMA PET/CT and PSMA PET/MRI, for the detection of intraprostatic tumours, regardless of the type of PSMA-ligand, was 86% (95% CI: 76-96%) and 97% (95% CI: 94-100%), respectively. Furthermore, the diagnostic accuracy for the detection of extraprostatic extension (EPE) was 73% (95% CI: 64-82%) and 77% (95% CI: 69-85%), while the diagnostic accuracy for the detection of seminal vesicle involvement (SVI) was 87% (95% CI: 80-93) and 90% (95% CI: 82-99%), respectively. CONCLUSION: The present investigation has demonstrated that PSMA PET/MRI surpasses currently recommended multiparametric magnetic resonance imaging (mpMRI) in terms of diagnostic accuracy as inferred from a notable data trajectory, whereas PSMA-PET/CT exhibited comparable diagnostic accuracy for intraprostatic tumour detection and T-staging compared to mpMRI. Nevertheless, the analysis has identified certain potential limitations, such as small-study effects and a potential for publication bias, which may impact the overall conclusions drawn from this study.
引用
- Gossili F, Mogensen AW, Konnerup TC, et al. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023. PMID: 37597010. doi:10.1007/s00259-023-06392-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。